NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance With Nasdaq Continued Listing Rules
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance With Nasdaq Continued Listing Rules
ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the closing of a private placement offering consisting of the issuance and sale of 806,452 common shares, par value CHF 0.80 per share and common share purchase warrants to purchase 806,452 common shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million. The warrants have a term of five years and have an exercise price of $4.25 per share.
蘇黎世,瑞士/ ACCESSWIRE / 2024年10月15日 / NLS製藥有限公司(納斯達克: NLSP)(納斯達克: NLSPW)("NLS"或"公司")是一家瑞士臨床階段生物製藥公司,專注於爲患有罕見和複雜中樞神經系統疾病的患者發現和開發創新療法,今天宣佈閉市推出由發行和出售806,452股普通股、每股面值CHF 0.80瑞士法郎和購買806,452股普通股的普通股認購權組成的定向增發,總購買價格爲3.97美元,募集總收益爲320萬美元。認購權期限爲五年,行權價格爲每股4.25美元。
In addition, the Company closed a debt purchase agreement, with an accredited investor, pursuant to which in exchange for the satisfaction of the Company's debt in the aggregate amount of $4.0 million held by the investor, the Company agreed to issue 806,452 newly designated convertible preferred shares, at a purchase price of approximately $4.96. The preferred shares contain a conversion price of $4.96 per share. Pursuant to the debt purchase agreement, the Company agreed to grant the investor the right to purchase up to an additional $10.0 million worth of convertible preferred shares beginning six months after the closing and continuing for as long as the investor owns preferred shares.
此外,公司與一家合格投資者簽訂了債務購買協議,根據該協議,公司將發行約400萬美元的債務,以換取投資者持有的總額爲400萬美元的債務,公司同意以約4.96美元的價格發行806,452股新指定的可轉換優先股。優先股包含每股4.96美元的轉換價格。根據債務購買協議,公司同意授予投資者購買額高達1000萬美元的可轉換優先股的權利,購買權從閉市後六個月起生效,持續至投資者持有優先股。
NLS also announced that it believes it has regained compliance with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), due to the fact that its common shares have traded above $1.00 for ten consecutive trading days. In addition, due in part to the foregoing transactions, NLS announced that it believes that it satisfies the stockholders' equity requirement of at least $2.5 million pursuant to Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market.
NLS還宣佈認爲已恢復符合納斯達克上市規則5550(a)(2)的最低買盤價要求,因爲其普通股已在連續十個交易日以上1.00美元交易。此外,部分原因歸功於前述交易,NLS宣佈認爲自身符合至少250萬美元股東權益要求,符合納斯達克資本市場繼續上市的5550(b)(1)規則。
The securities described above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
上述證券是根據《1933年證券法》第4(a)(2)節的登記要求中修改("證券法")第506(b)規則下的豁免責任提供和出售的。這些證券未根據證券法或適用州證券法註冊。因此,除符合證券法的有效註冊聲明或適用的豁免登記要求及該州的證券法外,這些證券不得在美國以外的地方提供或出售。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新聞稿不構成銷售或發售此類證券的報價,也不會在任何未經任何此類狀態或管轄區的證券法規註冊或取得資格的情況下銷售這些證券。
About NLS Pharmaceutics Ltd.
關於NLS Pharmaceutics Ltd.
NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS是一家全球發展階段的生物製藥公司,與一流合作伙伴和國際知名科學家合作,專注於爲罕見和複雜中樞神經系統疾病患者的創新療法的發現和開發,這些患者有待醫療需求。總部設在瑞士,成立於2015年,NLS由一支經驗豐富的管理團隊領導,具有開發和推廣產品候選藥物的記錄。欲了解更多信息,請訪問。
Safe Harbor Statement
Safe Harbor聲明
This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws, including statements related to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. For example, the Company is using forward-looking statements when discussing the potential conversion of preferred shares or exercise of warrants and that it believes it is in compliance with applicable Nasdaq rules. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.
本新聞稿包含根據美國聯邦證券法明示或暗示的前瞻性陳述,包括與發行時間和完成、與發行相關的慣例收盤條件的滿足以及資金用途有關的陳述。例如,公司在討論優先股轉換或認股權行使潛力時使用前瞻性陳述,並表示公司相信自身符合適用的納斯達克規定。這些前瞻性陳述及其影響是僅基於納思達交易所管理層目前的期望,並受多種可能導致實際結果與前瞻性陳述描述不符的因素和不確定性的影響。除非法律另有規定,納思達交易所對公開發布對這些前瞻性陳述的任何修訂不承擔義務,以反映本日期後的事件或情況或反映出乎意料的事件的發生。有關影響納思達交易所的風險和不確定性的更詳細信息載於NLS截至2023年12月31日年度報告第20-F表的「風險因素」標題下,該報告已向美國證券交易委員會或SEC提交,可在SEC網站www.sec.gov上獲得,並載於納思達交易所隨後向SEC提交的申報文件中。
For additional information:
有關詳細信息:
Elena Thyen, CFO
NLS Pharmaceutics Ltd.
+41(0) 44 512 21 50
etp@nls-pharma.com
Elena Thyen,首席財務官
NLS製藥有限公司
+41(0) 44 512 21 50
etp@nls-pharma.com
SOURCE: NLS Pharmaceutics Ltd.
來源:NLS Pharmaceutics Ltd.
譯文內容由第三人軟體翻譯。